1. Home
  2. CGTX vs RMCO Comparison

CGTX vs RMCO Comparison

Compare CGTX & RMCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGTX
  • RMCO
  • Stock Information
  • Founded
  • CGTX 2007
  • RMCO 2021
  • Country
  • CGTX United States
  • RMCO United States
  • Employees
  • CGTX N/A
  • RMCO N/A
  • Industry
  • CGTX Biotechnology: Pharmaceutical Preparations
  • RMCO Multi-Sector Companies
  • Sector
  • CGTX Health Care
  • RMCO Miscellaneous
  • Exchange
  • CGTX Nasdaq
  • RMCO Nasdaq
  • Market Cap
  • CGTX 17.9M
  • RMCO 14.9M
  • IPO Year
  • CGTX 2021
  • RMCO N/A
  • Fundamental
  • Price
  • CGTX $0.43
  • RMCO $1.01
  • Analyst Decision
  • CGTX Strong Buy
  • RMCO
  • Analyst Count
  • CGTX 6
  • RMCO 0
  • Target Price
  • CGTX $8.30
  • RMCO N/A
  • AVG Volume (30 Days)
  • CGTX 2.8M
  • RMCO 8.0K
  • Earning Date
  • CGTX 05-06-2025
  • RMCO 03-21-2025
  • Dividend Yield
  • CGTX N/A
  • RMCO N/A
  • EPS Growth
  • CGTX N/A
  • RMCO N/A
  • EPS
  • CGTX N/A
  • RMCO N/A
  • Revenue
  • CGTX N/A
  • RMCO $695,792.00
  • Revenue This Year
  • CGTX N/A
  • RMCO N/A
  • Revenue Next Year
  • CGTX N/A
  • RMCO N/A
  • P/E Ratio
  • CGTX N/A
  • RMCO N/A
  • Revenue Growth
  • CGTX N/A
  • RMCO 46.15
  • 52 Week Low
  • CGTX $0.34
  • RMCO $0.70
  • 52 Week High
  • CGTX $2.95
  • RMCO $1.63
  • Technical
  • Relative Strength Index (RSI)
  • CGTX 27.35
  • RMCO 39.94
  • Support Level
  • CGTX $0.36
  • RMCO $0.98
  • Resistance Level
  • CGTX $0.45
  • RMCO $1.05
  • Average True Range (ATR)
  • CGTX 0.05
  • RMCO 0.06
  • MACD
  • CGTX -0.01
  • RMCO -0.01
  • Stochastic Oscillator
  • CGTX 23.66
  • RMCO 35.42

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

About RMCO Royalty Management Holding Corporation

Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.

Share on Social Networks: